Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2
Galle, Peter R., Kudo, Masatoshi, Llovet, Josep M., Finn, Richard S., Karwal, Mark, Pezet, Denis, Kim, Tae-You, Yang, Tsai-Sheng, Zagonel, Vittorina, Tomasek, Jiri, Phelip, Jean Marc, Touchefeu, Yann, Koh, Su-Jin, Stirnimann, Guido, Wang, Chunxiao, Ogburn, Kenyon, Abada, Paolo, Widau, Ryan C., Zhu, Andrew X.
Published in Journal of clinical oncology (01.02.2020)
Published in Journal of clinical oncology (01.02.2020)
Get full text
Journal Article
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)
Zhu, Andrew X., Galle, Peter R., Kudo, Masatoshi, Finn, Richard S., Yang, Ling, Abada, Paolo, Llovet, Josep M.
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Finn, Richard S., Chan, Stephen L., Zhu, Andrew X., Knox, Jennifer J., Cheng, Ann-Lii, Siegel, Abby B., Bautista, Oliver, Kudo, Masatoshi
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3
Finn, Richard S., Cristofanilli, Massimo, Ettl, Johannes, Gelmon, Karen A., Verma, Shailendra, Colleoni, Marco, Giorgetti, Carla, Gauthier, Eric Roland, Liu, Yuan, Lu, Dongrui (Ray), Bartlett, Cynthia Huang, Slamon, Dennis J., Turner, Nicholas C., Rugo, Hope S.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies
Verma, Sunil, Im, Seock-Ah, Ro, Jungsil, Bondarenko, Igor, Masuda, Norikazu, Colleoni, Marco, Verma, Shailendra, Schnell, Patrick, Bananis, Eustratios, Lu, Dongrui (Ray), Ettl, Johannes, Cristofanilli, Massimo, Rugo, Hope S., Finn, Richard S.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Ikeda, Masafumi, Sung, Max W., Kudo, Masatoshi, Kobayashi, Masahiro, Baron, Ari David, Finn, Richard S., Kaneko, Shuichi, Zhu, Andrew X., Kubota, Tomoki, Kraljevic, Silvija, Ishikawa, Kohei, Siegel, Abby B., Kumada, Hiromitsu, Okusaka, Takuji
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
Qin, Shukui, Finn, Richard S., Kudo, Masatoshi, Meyer, Tim, Vogel, Arndt, Ducreux, Michel, Mercade, Teresa Macarulla, Tomasello, Gianluca, Boisserie, Frederic, Hou, Jeannie, Li, Cindy, Song, James, Zhu, Andrew X.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma
Zhu, Andrew X., Knox, Jennifer J., Kudo, Masatoshi, Chan, Stephen L., Finn, Richard S., Siegel, Abby B., Ma, Junshui, Watson, Pat, Cheng, Ann-Lii
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article
KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma
Finn, Richard S., Chan, Stephen L., Zhu, Andrew X., Knox, Jennifer J., Cheng, Ann-Lii, Siegel, Abby B., Bautista, Oliver, Watson, Pat, Kudo, Masatoshi
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article
Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for CCND1, 2 or 3 amplified tumors
Clark, Amy S., Hong, Fangxin, Finn, Richard S., DeMichele, Angela M., Mitchell, Edith P., Zweibel, James, Arnaldez, Fernanda I., McShane, Lisa M., Li, Shuli, Gray, Robert J., Rubenstein, Larry V., Patton, David, Williams, P Mickey, Hamilton, Stanley R., Copur, Mehmet S., Kasbari, Sameer S., Thind, Ravneet, Conley, Barbara A., O'Dwyer, Peter J., Harris, Lyndsay N., Arteaga, Carlos L., Chen, Alice P., Flaherty, Keith T.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts)
Mercade, Teresa Macarulla, Moreno, Victor, John, Binu, Morris, John Charles, Sawyer, Michael B., Yong, Wei Peng, Gutierrez, Martin, Karasic, Thomas Benjamin, Sangro, Bruno, Sheng-Shun, Yang, Gentry, Carleen, Kim, Amy, Kumar, Pavan, MacKenzie, Crystal, Rioux, Nathalie, Schindler, Joanne, Selvaraj, Anand, Finn, Richard S.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2)
Llovet, Josep M, Yen, Chia-Jui, Finn, Richard S., Kang, Yoon-Koo, Kudo, Masatoshi, Galle, Peter R., Assenat, Eric, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Borg, Christophe, Hiriart, Jean-Baptiste, Daniele, Bruno, Berg, Thomas, Chung, Hyun Cheol, Godinot, Nathalie, Wang, Chunxiao, Hsu, Yanzhi, Schelman, William R., Zhu, Andrew X.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Somatic copy number profiling of hepatocellular carcinoma circulating tumor cells
Court, Colin MacDonald, Hou, Shuang, Winograd, Paul, Sadeghi, Saeed, Finn, Richard S., Song, Min, Kaldas, Fady M, Busuttil, Ronald W, Graeber, Thomas, Tomlinson, James S, Tseng, Hsian-Rong, Agopian, Vatche G
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Yarchoan, Mark, Agarwal, Parul, Villanueva, Augusto, Rao, Shuyun, Dawson, Laura, Karasic, Thomas, Llovet, Joseph, Finn, Richard, Groopman, John, El-Serag, Hashem, Monga, Satdarshan, Wang, Xin Wei, Karin, Michael, Schwartz, Robert, Tanabe, Kenneth, Roberts, Lewis, Gunaratne, Preethi, Tsung, Allan, Brown, Kimberly, Lawrence, Theodore, Salem, Riad, Singal, Amit, Kim, Amy, Rabiee, Atoosa, Resar, Linda, Meyer, Jeffrey, Hoshida, Yujin, He, Aiwu Ruth, Ghoshal, Kalpana, Ryan, Patrick, Jaffee, Elizabeth, Guha, Chandan, Mishra, Lopa, Coleman, Norman, Ahmed, Mansoor
Published in Cancer research (Chicago, Ill.) (15.11.2019)
Published in Cancer research (Chicago, Ill.) (15.11.2019)
Get full text
Journal Article
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Canonici, Alexandra, Gijsen, Merel, Mullooly, Maeve, Bennett, Ruth, Bouguern, Noujoude, Pedersen, Kasper, O'Brien, Neil A, Roxanis, Ioannis, Li, Ji-Liang, Bridge, Esther, Finn, Richard, Siamon, Dennis, McGowan, Patricia, Duffy, Michael J, O'Donovan, Norma, Crown, John, Kong, Anthony
Published in Oncotarget (01.10.2013)
Published in Oncotarget (01.10.2013)
Get full text
Journal Article
Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)
Sung, Max W., Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Kudo, Masatoshi, Tateishi, Ryosuke, Ikeda, Masafumi, Breder, Valery, Rau, Kun-Ming, Ma, Yuk Ting, Alsina, Angel, Ryoo, Baek-Yeol, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina E., Tamai, Toshiyuki, Saito, Kenichi, Piscaglia, Fabio
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article
Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT)
Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Piscaglia, Fabio, Ueshima, Kazuomi, Aikata, Hiroshi, Vogel, Arndt, Lopez, Carlos, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel H., Dutcus, Corina E., Tamai, Toshiyuki, Saito, Kenichi, Lencioni, Riccardo
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article
Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study
Finn, Richard S., Kudo, Masatoshi, Kang, Yoon-Koo, Yen, Chia-Jui, Galle, Peter R., Llovet, Josep, Assenat, Eric, Brandi, Giovanni, Lim, Ho Yeong, Pracht, Marc, Rau, Kun Ming, Merle, Philippe, Motomura, Kenta, Ohno, Izumi, Daniele, Bruno, Shin, Dongbok, Gerken, Guido, Abada, Paolo, Hsu, Yanzhi, Zhu, Andrew X.
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article